Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Elucidation of Biomarkers for Muscle Invasion in Bladder Cancer
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1499
Bladder cancer is a common malignancy; it is the 4th most common cancer in males and the 9th in females. The presenting symptom is usually blood in...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Bladder cancer is a common malignancy; it is the 4th most common cancer in males and the 9th in females. The presenting symptom is usually blood in the urine, and diagnosis is currently based on cystoscopy, which is invasive, costly, painful and time consuming.

Aims/Hypothesis

To date, no biomarker has been identified in the urine that might be used for screening, staging, prognosis and monitoring treatment.

Research

We now report that the amount of the 60 kDa heat shock protein (HSP60) in a subject's urine is a biomarker for muscle invasion in patients with bladder cancer stage T2 and higher. Moreover, subjects with stage T1 disease can be stratified by their urine levels of HSP60 into a sub-group likely to progress into stage T2 or into a sub-group more likely to respond to conservative treatment with BCG, which does not require removal of the bladder. The distinction between these two sub-groups of T1 bladder cancer can identify earlier subjects in need of cystectomy, while sparing others unnecessary major surgery. Screening subjects with overt hematuria, or at risk of developing bladder cancer (such as heavy smokers).

Conclusion

Our research shows the diagnostic potential of a quantitative measurement of HSP60 levels in a subject's urine by ELISA, radio-immunoassay or other simple assay.

Relevance/Opportunity

Please enquire regarding licensing or codevelopment partnerships quoting reference no. 1499.
FEATURED
Last Updated May 2015
Technology Type DIAGNOSTIC
Phase of Development PRECLINICAL
CORPORATION